Straits Times Index
3,187.66 +32.97 (+1.05%) S&P 500
5,010.84 -11.37 (-0.23%) Dow
37,760.81 +7.50 (+0.02%) Nasdaq
15,610.82 -72.55 (-0.46%) Bitcoin USD
63,001.04 +1,363.64 (+2.21%) CMC Crypto 200
885.54 0.00 (0.00%)
ABBV Jun 2024 230.000 put
| Previous close | 93.71 |
| Open | 93.63 |
| Bid | 81.60 |
| Ask | 83.25 |
| Strike | 230.00 |
| Expiry date | 2024-06-21 |
| Day's range | 93.63 - 93.71 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
PR NewswirePhase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
AbbVie (NYSE: ABBV) today announced positive top-line results from SELECT-GCA, a Phase 3, multicenter, randomized, double-blind, placebo-controlled study, showing upadacitinib (RINVOQ®; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remissiona from week 12 through week 52 in adults with giant cell arteritis (GCA). In this study, 46 percent of patients receiving upadacitinib 15 mg in combination with a 26-week steroid taper regime
ZacksAbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know
AbbVie (ABBV) closed at $164.25 in the latest trading session, marking a +1.05% move from the prior day.
- Reuters
UPDATE 1-US FDA warns of harmful reactions to fake Botox injections
The U.S. Food and Drug Administration on Tuesday alerted health care professionals and consumers that unsafe counterfeit versions of AbbVie's Botox were given to consumers for cosmetic purposes in multiple states. The U.S. Centers for Disease Control and Prevention (CDC) and the FDA are investigating reports of harmful reactions among people who received injections of counterfeit Botox. As of April 12, a total of 19 people from nine states had reported harmful reactions after receiving Botox injections from unlicensed or untrained individuals, or in non-healthcare settings, such as homes and spas, according to the CDC.
